Stock Track | Ascendis Pharma Soars 6% After Hours on Q4 Beat, Buyback Plan

Stock Track

02-13

Ascendis Pharma A/S (ASND) shares surged 6.03% in after-hours trading on Wednesday, following the company's better-than-expected fourth quarter 2024 earnings and revenue fueled by robust sales of its products SKYTROFA and YORVIPATH.

The Danish drugmaker announced a share repurchase program of up to $18.25 million to buy back its American Depositary Shares (ADSs). It also plans to net settle certain Restricted Stock Units (RSUs) for around $9 million, preserving a total of approximately 200,000 ADSs held as treasury shares.

Ascendis reported Q4 2024 revenue of €173.9 million, beating estimates of €111.2 million, driven by strong demand for its growth hormone deficiency treatment SKYTROFA and hypoparathyroidism drug YORVIPATH. The company expressed confidence in continued strong revenue growth, aided by potential label expansions and new product launches in the pipeline, including its TransCon CNP drug for achondroplasia in children.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1142639987"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1142639987\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1142639987?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-13 05:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142639987","market":"us","top_or_hot":-1,"title":"Stock Track | Ascendis Pharma Soars 6% After Hours on Q4 Beat, Buyback Plan","media":"Stock Track","content":"<p>Ascendis Pharma A/S (ASND) shares surged 6.03% in after-hours trading on Wednesday, following the company's better-than-expected fourth quarter 2024 earnings and revenue fueled by robust sales of its products SKYTROFA and YORVIPATH.</p>\n\n<p>The Danish drugmaker announced a share repurchase program of up to $18.25 million to buy back its American Depositary Shares (ADSs). It also plans to net settle certain Restricted Stock Units (RSUs) for around $9 million, preserving a total of approximately 200,000 ADSs held as treasury shares.</p>\n\n<p>Ascendis reported Q4 2024 revenue of €173.9 million, beating estimates of €111.2 million, driven by strong demand for its growth hormone deficiency treatment SKYTROFA and hypoparathyroidism drug YORVIPATH. The company expressed confidence in continued strong revenue growth, aided by potential label expansions and new product launches in the pipeline, including its TransCon CNP drug for achondroplasia in children.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Ascendis Pharma Soars 6% After Hours on Q4 Beat, Buyback Plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Ascendis Pharma Soars 6% After Hours on Q4 Beat, Buyback Plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-13 05:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ascendis Pharma A/S (ASND) shares surged 6.03% in after-hours trading on Wednesday, following the company's better-than-expected fourth quarter 2024 earnings and revenue fueled by robust sales of its products SKYTROFA and YORVIPATH.</p>\n\n<p>The Danish drugmaker announced a share repurchase program of up to $18.25 million to buy back its American Depositary Shares (ADSs). It also plans to net settle certain Restricted Stock Units (RSUs) for around $9 million, preserving a total of approximately 200,000 ADSs held as treasury shares.</p>\n\n<p>Ascendis reported Q4 2024 revenue of €173.9 million, beating estimates of €111.2 million, driven by strong demand for its growth hormone deficiency treatment SKYTROFA and hypoparathyroidism drug YORVIPATH. The company expressed confidence in continued strong revenue growth, aided by potential label expansions and new product launches in the pipeline, including its TransCon CNP drug for achondroplasia in children.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ASND","symbol_name":"Ascendis Pharma A/S","start_time":0,"source_url":"","article_id":"1142639987","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142639987","pubTimestamp":1739396320,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Ascendis Pharma A/S  shares surged 6.03% in after-hours trading on Wednesday, following the company's better-than-expected fourth quarter 2024 earnings and revenue fueled by robust sales of its products SKYTROFA and YORVIPATH.The Danish drugmaker announced a share repurchase program of up to $18.25 million to buy back its American Depositary Shares . It also plans to net settle certain Restricted Stock Units  for around $9 million, preserving a total of approximately 200,000 ADSs held as treasur","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ASND":"Ascendis Pharma A/S"},"translate_title":"股票追踪Ascendis Pharma因第四季度业绩和回购计划盘后飙升6%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ASND":1},"content_text":"Ascendis Pharma A/S (ASND) shares surged 6.03% in after-hours trading on Wednesday, following the company's better-than-expected fourth quarter 2024 earnings and revenue fueled by robust sales of its products SKYTROFA and YORVIPATH.\nThe Danish drugmaker announced a share repurchase program of up to $18.25 million to buy back its American Depositary Shares (ADSs). It also plans to net settle certain Restricted Stock Units (RSUs) for around $9 million, preserving a total of approximately 200,000 ADSs held as treasury shares.\nAscendis reported Q4 2024 revenue of €173.9 million, beating estimates of €111.2 million, driven by strong demand for its growth hormone deficiency treatment SKYTROFA and hypoparathyroidism drug YORVIPATH. The company expressed confidence in continued strong revenue growth, aided by potential label expansions and new product launches in the pipeline, including its TransCon CNP drug for achondroplasia in children.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"buyback,movement","news_rank":0,"symbols":[],"gpt_button":1}}}